TITLE

Two drugs approved for chronic hepatitis C infection

AUTHOR(S)
Traynor, Kate
PUB. DATE
July 2011
SOURCE
American Journal of Health-System Pharmacy;7/1/2011, Vol. 68 Issue 13, p1176
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the FDA's approval of two hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir, marketed as Victrelis by Merck and telaprevir, marketed as Incivek by Vertex Pharmaceuticals, for the treatment of adults with chronic HCV infection caused by genotype 1 viruses. Details related to the treatment regimens of boceprevir and telaprevir therapies, their recommended dosage and common adverse events and risks associated with them are discussed. INSET: New drugs and dosage forms.
ACCESSION #
62548631

 

Related Articles

  • FDA approves two hepatitis C treatments.  // Infectious Disease News;Dec2013, Vol. 26 Issue 12, p7 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the once-daily oral nucleotide analog sofosbuvir and simeprevir for the treatment of hepatitis C virus infection as of December 2013.

  • Two new approvals bring hope to patients with hepatitis C. TANZI, MARIA G. // Pharmacy Today;Oct2015, p46 

    The article discusses the approval of two drugs Daclatasvir and a combination of Ombitasvir, paritaprevir, and ritonavir by the Food and Drug Association (FDA) and notes that these drugs helps in treating hepatitis C.

  • Two new hep C meds approved. Highleyman, Liz // Bay Area Reporter;6/16/2011, Vol. 41 Issue 24, p1 

    The article reports on the approval of the first two antiviral drugs for the treatment of chronic hepatitis C, such as boceprevir (Victrealis) from Merck & Co. Inc. and telaprevir (Incivek) from Vertex Pharmaceuticals Inc., by the U.S. Food and Drug Administration.

  • Gilead golden in HCV for now but many others in the wings. Powers, Marie // BioWorld Insight;2/3/2014, Vol. 22 Issue 5, p1 

    The article reports that Gilead Sciences Inc., biopharmaceutical company had launched Sofosbuvir (brand name Sovaldi) for treatment of Chronic Hepatitis C virus (HCV) infection. Topics discussed include the U.S. Food and Drug Administration approves Gilead Sovaldi for HCV infection, 80 oral HCV...

  • OraSure submits a PMA to FDA for quick HCV test.  // Medical Technology & Devices Week;11/3/2008, Vol. 6 Issue 44, p5 

    The article reports on the submission by OraSure Technologies of a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for what is said to be the first rapid test for antibodies to the hepatitis C virus (HCV). Through the application, the company is seeking...

  • Two New Drugs Approved for Treatment of Hepatitis C.  // Neurology Alert;Jul2011 Pharmacology Watch, p1 

    The article reports on the approval of two drugs by the U.S. Food and Drug Administration for the treatment of Hepatitis C. Merck's boceprevir is indicated for adults with hepatitis C who still retain some liver function and have had no previous or failed drug therapy. Vertex Pharmaceutical's...

  • Two New Drugs Approved for Treatment of Hepatitis C.  // Infectious Disease Alert;Jul2011 Pharmacology Watch Supplemt, p1 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of two hepatitis C drugs which include Victrelis or boceprevir from Merck and Incivek or telaprevir from Vertex Pharmaceutical. Both drugs have similar indications and are protease inhibitors. Boceprevir is to be...

  • Two New Drugs Approved for Treatment of Hepatitis C.  // Primary Care Reports;Jul2011 Pharmacology Watch, p1 

    The article reports on the approvals given by the U.S. Food and Drug Administration (FDA) to boceprevir from Merck and telaprevir from Vertex Pharmaceutical for use in the treatment of hepatitis C in 2011. It notes that both drugs are classified as protease inhibitors and hold the same...

  • WEEK IN WASHINGTON.  // BioWorld Insight;5/2/2011, Vol. 19 Issue 18, p6 

    The article reports on the recommendation of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to approve the drugs boceprevir of Merck & Co. Inc. and telaprevir of Vertex Pharmaceuticals Inc. for treatment of hepatitis C., along with its approval of...

  • Advanced Hepatitis Drug Nears FDA Approval. CHAMBERS, HEATHER // San Diego Business Journal;11/23/2009, Vol. 30 Issue 47, p3 

    The article reports on the plan of Vertex Pharmaceuticals Inc., a maker of HIV Treatment Lexiva, to submit telaprevir, a drug candidate to the Food and Drug Administration (FDA) approval, in San Diego, California. It states that the drug is intended to treat chronic hepatitis C virus infections...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics